Свободно-циркулирующая ДНК плазмы крови. Возможности применения в онкологии

Автор: Телышева Е.Н.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 2 т.17, 2017 года.

Бесплатный доступ

В обзоре представлены данные о свободно-циркулирующей ДНК (сцДНК) плазмы крови, ее биологических свойствах. Подробно рассматриваются возможности и ограничения применения анализа сцДНК плазмы крови в онкологической практике. Приведена характеристика современных высокочувствительных методов, с помощью которых можно проводить анализ сцДНК плазмы крови.

Соматические мутации, биомаркеры, свободно-циркулирующая днк (сцднк), "жидкостная биопсия"

Короткий адрес: https://sciup.org/14955544

IDR: 14955544

Список литературы Свободно-циркулирующая ДНК плазмы крови. Возможности применения в онкологии

Тамкович С.Н., Власов В.В., Лактионов П.П. Циркулирующие ДНК крови и их использование в медицинской диагностике. Молекулярная биология. 2008. Т. 42. № 1. С. 12-23.
Atamaniuk J., Vidotto C., Tschan H., et al. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin Chem. 2004. V. 50. N. 9. P. 1668-1670.
Catarino R., Ferreira M.M., Rodrigues H., et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 2008. V. 27. N. 8. P. 415-421.
Chan K.C., Jiang P., Zheng Y.W., et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. 2013. V. 59. N. 1. P. 211-224.
Chang H.W., Lee S.M., Goodman S.N., et al. Assessment of plasma DNA levels, allelic imbalance, and CA-125 as diagnostic tests for cancer. J Natl Cancer Inst. 2002. V. 94. N. 22. P. 1697-1703.
Chelobanov B.P., Laktionov P.P., Kharkova M.V., et al. Isolation of nucleic acid binding proteins: an approach for isolation of cell surface, nucleic acid binding proteins. Ann N Y Acad Sci. 2004. V. 1022. P. 239-243.
Chen K. Z., Lou F., Yang F., et al. Circulating tumor DNA detection in early-stage non-small cell-lung cancer patients by targeted sequencing. Scientific Reports. 2016. V. 6. Article ID 31985 DOI: 10.1038/srep31985
Chen X.Q., Stroun M., Magnenat J.L., et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996. V. 2. N. 9. P. 1033-1035.
Choi J.J., Reich C.F., Pisetsky D.S. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology. 2005. V. 115. N. 1. P. 55-62.
Dawson S.J., Tsui D.W., Murtaza M., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013. V. 368. N. 13. P. 1199-1209.
Dianxu F., Shengdao Z., Tianquan H., et al. A prospective study of detection of pancreatic carcinoma by combined plasma KRAS mutations and serum CA19-9 analysis. Pancreas. 2002. V. 25. N. 4. P. 336-341.
Diaz L.A.Jr, Williams R.T., Wu J., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012. V. 486. N. 7404. P. 537-540.
Diehl F., Schmidt K., Choti M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008. V. 14. N. 9. P. 985-990.
Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer -a survey. Biochim Biophys Acta. 2007. V. 1775. N. 1. P. 181-232.
Forshew T., Murtaza M., Parkinson C., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012. V. 4. N. 136. 136ra68.
Fournie J., Martres F., Pourrat J.P., et al. Plasma DNA as cell death marker in elderly patients. Gerontology. 1993. V. 39. N. 4. P. 215-221.
Frattini M., Gallino G., Signoroni S., et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 2008. V. 263. N. 2. P. 170-181.
Gahan P.B., Anker P., Stroun M. Metabolic DNA as the origin of spontaneously released DNA? Ann N Y Acad Sci. 2008. V. 1137. P.7-17 DOI: 10.1196/annals.1448.046
García-Olmo D.C., Picazo M.G., Toboso I., et al. Quantitation of cell-free DNA and RNA in plasma during tumor progression in rats. Mol Cancer. 2013. V.12:8. 12-8 DOI: 10.1186/1476-4598-
Gautschi O., Bigosch C., Huegli B., et al. Circulating deoxyribonucleic acid as prognostic marker in nonsmall-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004. V. 22. N. 20. P. 4157-4164.
Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012. V. 366. N. 10. P. 883-892.
Gold B., Cankovic M., Furtado L.V., et al. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn. 2015. V. 17. N. 3. P. 209-224.
González-Masiá J.A., García-Olmo D., García-Olmo D.C. Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther. 2013. V. 6. P.819-832 DOI: 10.2147/OTT.S44668
Gormally E., Caboux E., Vineis P., et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007. V. 635. N. 2-3. P. 105-117.
Hashad D., Sorour A., Ghazal A., et al. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal. 2012. V. 26. N. 6. P. 467-472.
Heitzer E., Ulz P., Belic J., et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 2013. V. 5. N. 4:30 DOI: 10.1186/gm434
Holdhoff M., Schmidt K., Donehower R., et al. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst. 2009. V. 101. N. 18. P. 1284-1285.
Jacobs E.L., Haskell C.M. Clinical use of tumor markers in oncology. Curr Probl Cancer. 1991. V. 15. N. 6. P. 299-360.
Jahr S., Hentze H., Englisch S., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001. V. 61. N. 4. P. 1659-1665.
Jung K., Fleischhacker M., Rabien A. Cell-free DNA in the blood as a solid tumor biomarker a critical appraisal of the literature. Clin Chim Acta. 2010. V. 411. N. 21-22. P. 1611-1624.
Kopreski M.S., Benko F.A., Borys D.J., et al. Somatic mutation screening: identification of individuals harboring KRAS mutations with the use of plasma DNA. J Natl Cancer Inst. 2002. V. 92. N. 11. P. 918-923.
LaFramboise T. Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res. 2009. V. 37. N. 13. P. 4181-4193.
Laktionov P.P., Tamkovich S.N., Rykova E.Y., et al. Cell-surface-bound nucleic acids: free and cell-surface-bound nucleic acids in blood of healthy donors and breast cancer patients. Ann N Y Acad Sci. 2004. V. 1022. P. 221-227.
Laktionov P.P., Tamkovich S.N., Rykova E.Y., et al. Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids. 2004. V. 23. N. 6-7. P. 879-883.
Leary R.J., Sausen M., Kinde I., et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012. V. 4. N. 162. 162ra154.
Leon S.A., Shapiro B., Sklaroff D.M., et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977. V. 37. N. 3. P. 646-650.
Li C.N., Hsu H.L., Wu T.L., et al. Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J Clin Lab Anal. 2003. V. 17. N. 4. P. 103-107
Lo Y.M., Rainer T.H., Chan L.Y., et al. Plasma DNA as a prognostic marker in trauma patients. Clin Chem. 2000. V. 46. N. 3. P. 319-323.
Luis A., Diaz L.A.Jr, Bardelli A. Liquid Biopsies: Genotyping Circulating Tumor DNA. J Clin Oncol. 2014. V. 32. N. 6. P. 579-586.
Mäbert K., Cojoc M., Peitzsch C., et al. Cancer biomarker discovery: current status and future perspectives. Int Radiat Biol. 2014. V. 90. N. 8. P. 659-677.
Maebo A. Plasma DNA level as a tumor marker in primary lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi. 1990. V. 28. N. 8. P. 1085-1091.
Maire F., Micard S., Hammel P., et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer. 2002. V. 87. N. 5. P. 551-554.
Ma M., Zhu H., Zhang C., et al. "Liquid biopsy" -ctDNA detection with great potential and challenges. Ann Transl Med. 2015. V. 3. N. 16. P. 235.
Misale S., Yaeger R., Hobor S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012. V. 486. N. 7404. P. 532-536.
Murtaza M., Dawson S.J., Tsui D.W., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013. V. 497. N. 7447. P. 108-112.
Nawroz-Danish H., Eisenberger C.F., Yoo G.H., et al. Microsatellite analysis of serum DNA in patients with head and neck cancer. Int J Cancer. 2004. V. 111. N. 1. P. 96-100.
Overman M.J., Modak J., Kopetz S., et al. Use of research biopsies in clinical trials: Are risks and benefits adequately discussed? J. Clin Oncol. 2013. V. 31. N. 1. P. 17-22.
Paci M., Maramotti S., Bellesia E., et al. Circulating plasma DNA as diagnostic biomarker in non-small cell Lung Cancer. Lung Cancer. 2009. V. 64. N. 1. P. 92-97.
Patel K.M., Tsui D.W. The translational potential of circulating tumour DNA in oncology. Clin. Biochem. 2015. V. 48. N. 15. P. 957-961.
Rachiglio A. M., Abate R. E., Sacco A. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget. 2016. V. 7. N. 41. P. 66595-66605.
Schwarzenbach H., Müller V., Stahmann N., et al. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann. N Y Acad. Sci. 2004. V. 1022. P. 25-32.
Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011. V. 11. N. 6. P. 426-437.
Shapiro B., Chakrabarty M., Cohn E.M., et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983. V. 51. N. 11. P. 2116-2120.
Shinozaki M., O’Day S. J., Kitago M., et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res. 2007. V. 13. N. 7. P. 2068-2074.
Shu X.O., Long J., Lu W., et al. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res. 2012. V. 72. N. 5. P. 1182-1189.
Sozzi G., Conte D., Mariani L., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001. V. 61. N. 12. P. 4675-4678.
Sozzi G., Conte D., Leon M., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003. V. 21. N. 21. P. 3902-3908.
Sorenson G.D., Pribish D.M., Valone F.H., et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomarkers Prev. 1994. V. 3. N. 1. P. 67-71.
Stroun M., Anker P., Maurice P., et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989. V. 46. N. 5. P. 318-322.
Stroun M., Maurice P., Vasioukhin V., et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci. 2000. V. 906. P. 161-168.
Stroun M., Lyautey J., Lederrey C., et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001. V. 313. N. 1-2. P. 139-142.
Sunami E., Shinozaki M., Higano C.S., et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009. V. 55. N. 3. P. 559-567.
Szpechcinski A., Chorostowska-Wynimko J., Kupis W., et al. Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC. Expert Opin Biol Ther. 2012. V. 12 Suppl 1.S. 3-9 DOI: 10.1517/14712598.2012.668519
Tamkovich S.N., Bryzgunova O.E., Rykova E.Y., et al. Circulating nucleic acids in blood of healthy male and female donors. Clin Chem. 2005. V. 51. N. 7. P. 1317-1319.
Theodor L., Melzer E., Sologov M., et al. Detection of pancreatic carcinoma: diagnostic value of KRAS mutations in circulating DNA from serum. Dig Dis Sci. 1999. V. 44. N. 10. P. 2014-2019.
Thijssen M.A., Swinkels D.W., Ruers T.J., et al. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 2002. V. 22. N. 1A. P. 421-425.
Tomioka N., Morita K., Kobayashi N., et al. Array comparative genomic hybridization analysis revealed four genomic prognostic biomarkers for primary gastric cancers. Cancer Genet Cytogenet. 2010. V. 201. N. 1. P. 6-14.
Trombino S., Neri M., Puntoni R., et al. Mutations in KRASs codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer. Clin Chem. 2005. V. 51. N. 7. P. 1313-1314.
Tu M., Chia D., Wei F., et al. Liquid biopsy for etection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB). Analyst. 2016. V. 141. N. 2. P. 393-402.
Vasioukhin V., Anker P., Maurice P., et al. Point mutations of the NRAS gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994. V. 86. N. 4. P. 774-779.
Vogelstein B., Papadopoulos N., Velculescu V.E., et al. Cancer genome landscapes. Science. 2013. V. 339. N. 6127. P. 1546-1558.
Wu T.L., Zhang D., Chia J.H., et al. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta. 2002. V. 321. N. 1-2. P. 77-87.
Xie G.S., Hou A.R., Li L.Y., et al. Quantification of plasma DNA as a screening tool for lung cancer. Chin Med J Engl. 2004. V. 117. N. 10. P. 1485-1488.
Yoon K.A., Park S., Lee S.H., et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn. 2009. V. 11. N. 3. P. 182-185.
Zhang R., Shao F., Wu X., et al. Value of quantitative analysis of circulating cell-free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer. 2010. V. 69. N. 2. P. 225-231.

Еще

Статья научная